Cynapsus Therapeutic (CYNAF) 1.1000 $CYNAF
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
Business Wire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 1.35 (-0.02)
Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 115.01 (+2.51), AUPH: 3.46 (+0.01), HZNP: 16.84 (-0.41), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), TEVA: 56.77 (-0.58), ACOR: 36.14 (-0.51), PRTA: 22.89 (+0.13), NDRM: 10.76 (+0.22)
Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
Business Wire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.
CTH.VN: 1.240 (+0.040)
Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease?
Michael Hagan - Seeking Alpha - Tue Nov 25, 7:41AM CST
In the past several weeks, there has been an increase in stories appearing on companies that are involved in Parkinson's disease research. Acorda's (NASDAQ: ACOR ) buyout of Civitas Therapeutics, NeuroDerm's (NASDAQ: NDRM ) (IPO) and the...
ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Cynapsus up on Phase 2 data
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 12:16PM CST
Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Business Wire - Wed Nov 19, 5:00AM CST
--Conference call begins at 8:00 a.m. Eastern time today
CTH.VN: 1.240 (+0.040)
Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2014
Business Wire - Tue Nov 18, 3:40PM CST
--Conference call to present results to be held at 8:00 a.m. Eastern time
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent Developments
Marketwired - Tue Nov 11, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the on-demand rescue of OFF motor symptoms of Parkinson's disease, today announced financial results for the three and nine months ended September 30, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.VN: 1.240 (+0.040)
Acorda Therapeutics Hitting Its Stride As Company Momentum Accelerates
Michael Hagan - at Seeking Alpha - Sat Nov 01, 7:52AM CDT
ACOR: 36.14 (-0.51)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CHTP: 6.52 (-0.03), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), BCLI: 3.86 (-0.02), BSX: 14.98 (+0.24), IPXL: 39.51 (+0.69), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), CVTS: (), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), PRTA: 22.89 (+0.13), PRAN: 1.09 (-0.55), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch
Marketwired - Tue Oct 14, 5:02AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that its APL-130277 for Parkinson's was recognized as one of the Top Ten Neurology Projects to Watch by a joint selection committee including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. Dr. Tracy is also the editor of the respected biotechnology publication NeuroPerspective, which is utilized by pharmaceutical companies and investors around the world. Cynapsus has been invited to present the APL-130277 project at the Therapeutic Area Partnerships Meeting taking place on November 19 to 21, 2014, at the Hyatt Regency Boston.
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch
Thomson Reuters ONE - Tue Oct 14, 12:00AM CDT
October 14, 2014
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC
Thomson Reuters ONE - Tue Oct 07, 3:00PM CDT
PRESS RELEASE
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC
Marketwire Canada - Tue Oct 07, 3:00PM CDT
Cynapsus Therapeutics (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty pharmaceutical company, today announced Thierry Bilbault, Ph.D., has been named Chief Scientific Officer (CSO) and Executive Vice President of Chemistry, Manufacturing and Controls (CMC). In this role, Dr. Bilbault will lead the strategic CMC activities related to the Company's APL-130277 drug candidate, a convenient and easy to use sublingual thin film strip for the rescue of OFF motor symptoms of Parkinson's disease.
CTH.VN: 1.240 (+0.040), NVS: 102.20 (-0.17)
Cynapsus Therapeutics Announces Change of Auditor
Marketwire - Fri Sep 19, 7:01AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(TSX VENTURE: CTH)(OTCQX: CYNAF) announces that it has changed its auditor. McGovern, Hurley, Cunningham, LLP (the "Former Auditor" has resigned at the request of the Company, effective September 18, 2014. The Directors of the Company have appointed Ernst & Young LLP (the "Successor Auditor" of Toronto, Ontario as auditor for the Company, effective September 19, 2014 until the close of the Company's next Annual General Meeting. The change in auditor has been approved by Cynapsus' Audit Committee and Board of Directors.
CTH.VN: 1.240 (+0.040)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
Business Wire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 1.35 (-0.02)
Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 115.01 (+2.51), AUPH: 3.46 (+0.01), HZNP: 16.84 (-0.41), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), TEVA: 56.77 (-0.58), ACOR: 36.14 (-0.51), PRTA: 22.89 (+0.13), NDRM: 10.76 (+0.22)
Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
Business Wire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.
CTH.VN: 1.240 (+0.040)
Cynapsus Or Acorda - Whose Market Is It For Parkinson's Disease?
Michael Hagan - Seeking Alpha - Tue Nov 25, 7:41AM CST
In the past several weeks, there has been an increase in stories appearing on companies that are involved in Parkinson's disease research. Acorda's (NASDAQ: ACOR ) buyout of Civitas Therapeutics, NeuroDerm's (NASDAQ: NDRM ) (IPO) and the...
ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Cynapsus up on Phase 2 data
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 12:16PM CST
Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
Business Wire - Wed Nov 19, 5:00AM CST
--Conference call begins at 8:00 a.m. Eastern time today
CTH.VN: 1.240 (+0.040)
Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2014
Business Wire - Tue Nov 18, 3:40PM CST
--Conference call to present results to be held at 8:00 a.m. Eastern time
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent Developments
Marketwired - Tue Nov 11, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual thin film strip for the on-demand rescue of OFF motor symptoms of Parkinson's disease, today announced financial results for the three and nine months ended September 30, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.VN: 1.240 (+0.040)
Acorda Therapeutics Hitting Its Stride As Company Momentum Accelerates
Michael Hagan - at Seeking Alpha - Sat Nov 01, 7:52AM CDT
ACOR: 36.14 (-0.51)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 391.66 (-0.45), MNOV: 3.62 (-0.56), CHTP: 6.52 (-0.03), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), BCLI: 3.86 (-0.02), BSX: 14.98 (+0.24), IPXL: 39.51 (+0.69), AVNR: 16.96 (unch), ACAD: 34.21 (+0.37), CVTS: (), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), PRTA: 22.89 (+0.13), PRAN: 1.09 (-0.55), FOLD: 8.36 (-0.11), CUR: 3.41 (+0.13)
Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch
Marketwired - Tue Oct 14, 5:02AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that its APL-130277 for Parkinson's was recognized as one of the Top Ten Neurology Projects to Watch by a joint selection committee including Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. Dr. Tracy is also the editor of the respected biotechnology publication NeuroPerspective, which is utilized by pharmaceutical companies and investors around the world. Cynapsus has been invited to present the APL-130277 project at the Therapeutic Area Partnerships Meeting taking place on November 19 to 21, 2014, at the Hyatt Regency Boston.
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics' Phase 2 Drug Candidate for Parkinson's Chosen as One of the Top Ten Neurology Projects to Watch
Thomson Reuters ONE - Tue Oct 14, 12:00AM CDT
October 14, 2014
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC
Thomson Reuters ONE - Tue Oct 07, 3:00PM CDT
PRESS RELEASE
CTH.VN: 1.240 (+0.040)
Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC
Marketwire Canada - Tue Oct 07, 3:00PM CDT
Cynapsus Therapeutics (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty pharmaceutical company, today announced Thierry Bilbault, Ph.D., has been named Chief Scientific Officer (CSO) and Executive Vice President of Chemistry, Manufacturing and Controls (CMC). In this role, Dr. Bilbault will lead the strategic CMC activities related to the Company's APL-130277 drug candidate, a convenient and easy to use sublingual thin film strip for the rescue of OFF motor symptoms of Parkinson's disease.
CTH.VN: 1.240 (+0.040), NVS: 102.20 (-0.17)
Cynapsus Therapeutics Announces Change of Auditor
Marketwire - Fri Sep 19, 7:01AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(TSX VENTURE: CTH)(OTCQX: CYNAF) announces that it has changed its auditor. McGovern, Hurley, Cunningham, LLP (the "Former Auditor" has resigned at the request of the Company, effective September 18, 2014. The Directors of the Company have appointed Ernst & Young LLP (the "Successor Auditor" of Toronto, Ontario as auditor for the Company, effective September 19, 2014 until the close of the Company's next Annual General Meeting. The change in auditor has been approved by Cynapsus' Audit Committee and Board of Directors. CTH.VN: 1.240 (+0.040)
